Cannabix Technologies to participate in the October US South

Vancouver, British Columbia, Oct. 11, 2022 (Global News) – Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (“Company or Cannabix”) The developer of a marijuana breathalyzer device for law enforcement and the workplace reported that it will participate in a mid-October study date to test its A supplemental version of FAIMS, a technique for the detection of Δ9-tetrahydrocannabinol (“THC”) and related analytes in human breath, in a comprehensive multi-analytical study of cannabis-affected subjects in the southern United States. Cannabix participated in two test days in June and July in two different US cities. The October event will be held at a new location.inside American Southern Studies, Cannabix is ​​working with toxicologists and law enforcement officers who are testing subjects affected by marijuana. The company’s technology (proprietary breath capture and cannabis detection devices, described below) is being used in parallel with several traditional drug screening methods, including blood and oral fluid collection. In addition, a closed driving test is planned for the mid-October study date to assess impairments. Details of the study will be provided in due course upon the Company’s approval for disclosure.

Data from previous studies have shown remarkably consistent correlations of THC levels in direct comparisons between breath samples collected and analyzed using Cannabix hardware and current whole blood standards. The company’s handheld breath acquisition unit (“BCU”, Figure 1) and the newly developed laboratory “MS Breath Sampler” (Figure 2) are being used together to provide a new breakthrough method for drug testing to complement gold standard quality Mass Spectrometry (MS) and dramatically simplify laboratory analytical methods, reducing sample turnaround time (thereby minimizing operating costs) while maintaining sensitive, precise results.

The company has developed a unique breath capture system capable of collecting low volatility analytes, such as THC, from a sample of approximately 5 breaths. Additionally, Cannabix devices efficiently capture analytes, completely eliminating the sample preparation steps required by traditional methods. The system detects and confirms THC in breath up to 4 hours after smoking, and breath samples are stored and analyzed for up to two days after sample collection.

THC in breath and blood data

Cannabix has been actively involved in breath blood research throughout the year – with trials completed in Ontario (see May 9 press release)th2022) and law enforcement in the southern U.S. in June and July (see July 12 press release)th and August 25th, 2022). The findings showed that THC respiration levels were consistent between subjects over time, and the data showed a consistent correlation between THC levels in respiration and whole blood at early time points after smoking.

importance of learning

By participating in these blood-breath correlation studies, the company is using cutting-edge hardware developed by Cannabix to construct important real-world breath data for various cannabis users. These data significantly improve the accuracy or recency of use of metabolic measurements. Blood is currently the standard by which law enforcement and toxicologists measure drugs and is used in court as objective evidence of possible harm.

According to NHTSA report to Congress (2017)1 After you stop using it, THC in your blood drops rapidly. In contrast to alcohol, which is metabolized at a relatively steady rate, THC is metabolized at an exponentially decreasing rate, so THC blood levels first drop rapidly and then slowly drop as lower THC levels are reached. Within 30 minutes of smoking, blood and breath THC levels drop by as much as 80 to 90 percent from peak levels. The low levels were then held for only a few hours before returning to baseline levels. Because of this short window period, confirming the presence of the drug as soon as possible after law enforcement ceases is critical to provide accurate objective evidence of recent marijuana use in drug driving. The Cannabix device can be used to collect breath samples as soon as damage is suspected and can significantly reduce the time required for the entire drug confirmation process. The analysis time (1-2 minutes per sample) is much shorter than most current methods, enabling high-throughput operations and eliminating backlogs; it also speeds up administrative procedures. Cannabix devices are designed to be easy to use and seamlessly connect with techniques already familiar to toxicologists, requiring minimal training for all users.

Cannabix tools provide fast and non-invasive breath sample collection and easy analysis without sample preparation. In contrast, existing and traditional breath and saliva testing procedures require several sample extraction and preparation steps prior to analysis, and the analysis itself can take 1-3 hours per sample. This is expensive and impractical. Additionally, existing and traditional breath and saliva testing procedures often employ inefficient, time-consuming collection methods, and recovery rates are often still poor. Cannabix has developed unique breath testing methods that reduce costs and make operations and processes more efficient.

(1) Marijuana Impaired Driving (

Cannabix October 11, 2022 Figures 1 and 2

About Cannabix Technologies Inc.

Cannabis Technologies is a developer of cannabis breathalyzer technology for law enforcement and the workplace. Cannabix is ​​working to develop a drug screening device that will detect THC — the psychoactive component of marijuana, which can cause damage using a breath sample. A breath test for THC will allow employers and law enforcement to identify recent marijuana use to better align with impairments. The Cannabix device is in advanced prototype and preclinical testing stages.

We seek safe harbor.
Representing the Board of Directors

“Ralph Mlett”

cannabis technology companies

For more information, please contact the company

CSE has not reviewed and accepts no responsibility for the adequacy or accuracy of this press release.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking information that involves various risks and uncertainties in future events. Such forward-looking information may include, but is not limited to, statements that are based on current expectations, involve numerous risks and uncertainties, and are not guarantees of the company’s future performance, such as the final development of commercial or prototype products, successful trials or pilots of company technology, and are not guaranteed. There is no guarantee that commercial sales of any kind will actually materialize; there is no guarantee that the company will have sufficient funds to complete product development. There are a number of risks and uncertainties that could cause actual results and the company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks relating to the protection of know-how; ( iii) the Company’s ability to complete financing; (iv) the Company’s ability to develop and market its future products; (v) the potential inconsistencies with government regulation, management and maintenance of growth, the impact of adverse publicity, litigation, competition and the Company’s announcements and documents. risks associated with other factors identified at the time. There can be no assurance that the cannabis breathalyzer technology it develops will bring any benefit to the company, nor that any proposed new product will be manufactured, will be successful in beta testing or clinical trials. There is no guarantee that existing “patent-pending” technology licensed by the company will receive patent status from the regulator. The company does not currently sell commercial breathalyzers. Actual results and future events may differ materially from those anticipated in such information. These and all subsequent written and ubiquitous forward-looking information are based on management’s estimates and opinions as of the date such information is made and are fully limited by the express limitations of this notice. The company does not intend to update these forward-looking statements except as required by law.

Photos accompanying this announcement are available at

Source link